The first study that highlighted the possibility of using chemerin as a prognostic predictor in patients with dilated cardiomyopathy was recently published by Chen et al. The authors included 214 patients with DCM, and after a median follow-up of 18 months, revealed that patients with higher chemerin levels had an increased risk of major cardiovascular events. The gene discussed is RARRES2; the disease is dilated cardiomyopathy.